Jun 15, 2020
Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients
Jun 03, 2020
EULAR 2020: Lilly Shares New Data for Olumiant® in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Apr 10, 2020
Lilly Begins Clinical Testing of Therapies for COVID-19
Mar 16, 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Jan 27, 2020
Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine
Dec 16, 2019
Promising Early Launch Metrics for AbbVie's Rinvoq (upadacitinib) to Help JAK Inhibitors Solidify Their Position as Second-Line Leaders in Rheumatoid Arthritis, According to Spherix Global Insights
Aug 23, 2019
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis
Feb 04, 2019
Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
Jan 16, 2019
Recent Data Collected by Spherix Global Insights Highlights Key US vs. EU Differences Between Perceptions and Adoption of Eli Lilly's Olumiant and Pfizer's Xeljanz for the Treatment of Rheumatoid Arthritis
Nov 01, 2018
With availability of Olumiant(TM) (baricitinib), Lilly brings new oral treatment option for Canadians living with rheumatoid arthritis
Oct 21, 2018
ACR 2018: Lilly Shares Updated Safety Analysis of OLUMIANT® (baricitinib) in Patients with Moderately-to-Severely Active Rheumatoid Arthritis
Aug 20, 2018
US Rheumatologists' Early Views on Eli Lilly's Olumiant for the Treatment of Rheumatoid Arthritis Show Uphill Battle, While Pfizer's Xeljanz Holds Ground as the Preferred JAK Inhibitor
Jun 01, 2018
FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis
May 10, 2018
Warning to Eli Lilly's Olumiant (baricitinib): Entrenched First-to-Market Rheumatoid Arthritis Products are Tough to Unseat
Apr 23, 2018
FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
Nov 21, 2017
Recent Chart Audit Reveals Switching Rheumatoid Arthritis Patients to Roche/Genentech's RoActemra (Actemra) is Significantly More Common in the EU5 than it is in the US
Nov 05, 2017
ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo
Aug 30, 2017
Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018
Jul 25, 2017
Lilly and Incyte Provide Update on Baricitinib
Jun 16, 2017
New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017